Age-Driven Genetic and Epigenetic Heterogeneity in B-ALL

Area of Science:

• Hematologic Oncology
• Molecular Biology
• Genetics

Background:

• B-cell acute lymphoblastic leukemia (B-ALL) presents a significant clinical challenge due to its molecular heterogeneity across different age groups.
• Pediatric B-ALL typically has higher cure rates, while adult B-ALL is often more aggressive and treatment-resistant.

Purpose of the Study:

• To review the age-specific genetic and epigenetic landscapes contributing to B-ALL disparities.
• To elucidate how molecular alterations differ in their nature and timing, indicating distinct leukemogenic processes.

Main Methods:

• Comparative analysis of genetic aberrations in pediatric and adult B-ALL.
• Examination of age-dependent epigenetic modifications, including DNA methylation, histone modifications, and non-coding RNA expression.
• Review of mutations in key epigenetic regulators specific to different age groups.

Main Results:

• Pediatric B-ALL is characterized by favorable genetic aberrations like ETV6::RUNX1 and hyperdiploidy.
• Adult B-ALL frequently exhibits high-risk features such as BCR::ABL1 fusions and IKZF1 deletions.
• Distinct epigenetic profiles, including mutations in SETD2/CREBBP (pediatric) versus TET2/IDH1/2 (adult), are observed.

Conclusions:

• Age-driven molecular differences in B-ALL are not only prognostic but also mechanistic, reflecting unique developmental pathways.
• Understanding these age-specific molecular transitions is crucial for refining risk stratification.
• Tailoring precision therapies to the distinct biology of B-ALL across the lifespan is essential for improved patient outcomes.